Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Johan, Lantto"'
Autor:
Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang, Roberto R. Rosato
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival
Externí odkaz:
https://doaj.org/article/56ecc7c5000b4303a8e6a4a138fe027f
Autor:
Mikkel W. Pedersen, Morag Park, Thomas Bouquin, Johan Lantto, Michael Kragh, Ivan D. Horak, Helle J. Jacobsen, George F.Vande Woude, Dafna Kaufman, Karsten W. Eriksen, Sara Collins, Paolo Conrotto, Gunther R. Galler, Anna Dahlman, Klaus Koefoed, Thomas T. Poulsen, Serhiy Havrylov, Michael M. Grandal
Supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1502dd7ee904c7154708f598a0ed2ed5
https://doi.org/10.1158/1535-7163.22505550.v1
https://doi.org/10.1158/1535-7163.22505550.v1
Autor:
Mikkel W. Pedersen, Morag Park, Thomas Bouquin, Johan Lantto, Michael Kragh, Ivan D. Horak, Helle J. Jacobsen, George F.Vande Woude, Dafna Kaufman, Karsten W. Eriksen, Sara Collins, Paolo Conrotto, Gunther R. Galler, Anna Dahlman, Klaus Koefoed, Thomas T. Poulsen, Serhiy Havrylov, Michael M. Grandal
Supplementary figure 1. Sym015 inhibits viability of cell lines in a synergic manner; Supplementary figure 2. The Sym015 antibodies Hu9338 and Hu9006 bind to 2nd or 3rd blades of MET and block HGF binding; Supplementary figure 3. Sym015 induces MET i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88967022fe0e668bd3a4d1f94d334d40
https://doi.org/10.1158/1535-7163.22505553
https://doi.org/10.1158/1535-7163.22505553
Autor:
Mikkel W. Pedersen, Morag Park, Thomas Bouquin, Johan Lantto, Michael Kragh, Ivan D. Horak, Helle J. Jacobsen, George F.Vande Woude, Dafna Kaufman, Karsten W. Eriksen, Sara Collins, Paolo Conrotto, Gunther R. Galler, Anna Dahlman, Klaus Koefoed, Thomas T. Poulsen, Serhiy Havrylov, Michael M. Grandal
Increased MET activity is linked with poor prognosis and outcome in several human cancers currently lacking targeted therapies. Here, we report on the characterization of Sym015, an antibody mixture composed of two humanized IgG1 antibodies against n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f631dae511cbcf627268e992e4db5afc
https://doi.org/10.1158/1535-7163.c.6538110.v1
https://doi.org/10.1158/1535-7163.c.6538110.v1
Autor:
Michael Kragh, Johan Lantto, Ivan D. Horak, Lars S. Nielsen, Per-Johan Meijer, Thomas T. Poulsen, Ida Kjær, Anna Dahlman, Klaus Koefoed, Helle J. Jacobsen, Mikkel W. Pedersen
Short description of methods and materials used for supplemmentary figures. BioLayer Interferometry, ADCC and CDC assays.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a99955a72456cf0e33001b0af1f391d
https://doi.org/10.1158/1535-7163.22502472
https://doi.org/10.1158/1535-7163.22502472
Autor:
Michael Kragh, Johan Lantto, Ivan D. Horak, Lars S. Nielsen, Per-Johan Meijer, Thomas T. Poulsen, Ida Kjær, Anna Dahlman, Klaus Koefoed, Helle J. Jacobsen, Mikkel W. Pedersen
Supplementary Tables and Figures. Table S1 contains affinities for antibodies binding to HER2. Table S2 contains results from epitope bin analysis of the antibodies. Figure S1 shows a comparison of Perjeta and the pertuzumab analogue used in this pap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a03fc8b9d38e6012910a410bf03a66
https://doi.org/10.1158/1535-7163.22502469
https://doi.org/10.1158/1535-7163.22502469
Autor:
Paul M. Harari, Randall J. Kimple, Johan Lantto, Michael Kragh, Adam D. Swick, Zachary S. Morris, Chunrong Li, Craig Hullett, Lauryn R. Werner, Eric A. Armstrong, Shyhmin Huang, David M. Francis
Body weight of animals during xenograft experiements.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9e9708600ed2d3bde1d599edc445d1
https://doi.org/10.1158/1078-0432.22460193.v1
https://doi.org/10.1158/1078-0432.22460193.v1
Autor:
Paul M. Harari, Randall J. Kimple, Johan Lantto, Michael Kragh, Adam D. Swick, Zachary S. Morris, Chunrong Li, Craig Hullett, Lauryn R. Werner, Eric A. Armstrong, Shyhmin Huang, David M. Francis
Additional effect of Pan-HER and radiation on programmed cell death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7a757d7f9084231648a86b0d74d441
https://doi.org/10.1158/1078-0432.22460196
https://doi.org/10.1158/1078-0432.22460196
Autor:
Paul M. Harari, Randall J. Kimple, Johan Lantto, Michael Kragh, Adam D. Swick, Zachary S. Morris, Chunrong Li, Craig Hullett, Lauryn R. Werner, Eric A. Armstrong, Shyhmin Huang, David M. Francis
Purpose: Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers. Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d846f56ffce374d5f63c9a26ed0c42b
https://doi.org/10.1158/1078-0432.c.6524424.v1
https://doi.org/10.1158/1078-0432.c.6524424.v1
Autor:
Johan Lantto, Michael Kragh, Mikkel W. Pedersen, Ivan D. Horak, Christina R. Andersen, Bolette Bjerregaard, Dietmar Weilguny, Jette W. Sen, Klaus Koefoed, Ida Kjær, Anna Dahlman, Thomas T. Poulsen, Helle J. Jacobsen
Supplementary Figures S1-8. Figure S1 - Analysis of nonlinear blending synergy for the pairs of antibodies that constitute Pan-HER. Figure S2 - In vitro comparison of Pan-HER and a combination of cetuximab, trastuzumab and MM-121. Figure S3 - In vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3070cce3b363e6339b7b3ea62fc19ee0
https://doi.org/10.1158/1078-0432.22457522.v1
https://doi.org/10.1158/1078-0432.22457522.v1